🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

26 recruiting trials

for Synovial Sarcomas

Hypofractionated, 3-week, Preoperative Proton or X-ray Radiotherapy for Patients With Localized Soft Tissue Sarcoma NCT07169344Phase 24 sites📍 Bergen📍 Oslo📍 Tromsø Oslo University Hospital · Tests: preoperative, Quality of life, Functional outcome N-803 in Patients With Progressive Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Previously Treated With Adoptive Cellular Therapy NCT07261657EARLY Phase 11 site📍 Chicago Seth Pollack · Tests: Biospecimen Collection, Computed Tomography, Leukapheresis, Magnetic Resonance Imaging, Nogapendekin Alfa Inbakicept Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed). NCT06607692Phase 1, Phase 21 site📍 Boadilla del Monte Fundación de investigación HM · Tests: Olaparib; 177Lu-DOTATATE MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma NCT06277154Phase 21 site📍 Guangzhou HRYZ Biotech Co. · Tests: MASCT-I, Doxorubicin, Ifosfamide First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors NCT06644755Phase 17 sites📍 Boston📍 New York📍 Nashville Daiichi Sankyo · Tests: DS-2243a Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers NCT05296564Phase 1, Phase 21 site📍 Jerusalem Hadassah Medical Organization · Tests: CYCLOPHOSPHAMIDE and FLUDARABIN, Cyclophosphamide, HBI 0201-ESO TCRT, Aldesleukin NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) NCT06239272Phase 1, Phase 27 sites📍 Atlanta📍 Chicago📍 Baton Rouge St. Jude Children's Research Hospital · Tests: Surgical resection, Proton beam radiation therapy, Pazopanib, Ifosfamide, Doxorubicin A Study to Test the Safety, Tolerability and Effect of ZI-MA4-1 for Patients With Locally Advanced or Metastatic Solid Malignancies NCT07613723Phase 12 sites📍 London📍 Manchester Zelluna Immunotherapy AS · Tests: ZI-MA4-1 (TCR-NK cells), Cyclophosphamide, Fludarabine Sequential Infusion of CD146-Targeted and HER2-Targeted CAR T Cells in Patients With Advanced Sarcomas NCT07066982Phase 1, Phase 21 site📍 Beijing Essen Biotech · Tests: CD146/HER2 CAR-T cells Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial Sarcoma NCT07174427Phase 33 sites📍 Osaka📍 Fukuoka📍 Kashiwa Takara Bio Inc. · Tests: TBI-1301, Cyclophosphamide, Fludarabine Pasireotide as Maintenance Treatment in Synovial Sarcoma and Desmoplastic Small Round Cell Tumor NCT06456359Phase 24 sites📍 Heidelberg📍 Stuttgart📍 Stuttgart University Hospital Heidelberg · Tests: Signifor TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid Tumors NCT07713732Phase 13 sites📍 Camperdown📍 Malvern📍 Nedlands Treeline Biosciences, Inc. · Tests: TLN-499, Venetoclax Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS) NCT03016819Phase 324 sites📍 Phoenix📍 Los Angeles📍 Santa Monica Advenchen Laboratories, LLC · Tests: AL3818, Dacarbazine, AL3818 or placebo, Midazolam 2 mg for CYP3A4 phenotyping, Digoxin (0.25mg) AOH1996 for the Treatment of Refractory Solid Tumors NCT05227326Phase 13 sites📍 Scottsdale📍 Duarte📍 Long Beach City of Hope Medical Center · Tests: PCNA Inhibitor AOH1996 Dose-escalated, Hypofractionated, Definitive Proton Radiotherapy for Patients With Inoperable Soft Tissue Sarcoma. NCT07173972Phase 22 sites📍 Bergen📍 Oslo Oslo University Hospital · Tests: Definitive radiotherapy ACTengine® IMA203 Combined With mRNA-4203 NCT06946225Phase 14 sites📍 San Francisco📍 Boston📍 New York Immatics US, Inc. · Tests: IMA203, mRNA-4203 SPEARHEAD-3 Pediatric Study NCT05642455Phase 1, Phase 210 sites📍 Palo Alto📍 Bethesda📍 Boston USWM CT, LLC · Tests: Afamitresgene autoleucel XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma, Bone Sarcoma or Translocation-associated Soft Tissue Sarcoma NCT06571734Phase 21 site📍 Chicago Northwestern University · Tests: Biospecimen Collection, Computed Tomography, Echocardiography, Multigated Acquisition Scan, Zanzalintinib Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1 NCT06083883Phase 11 site📍 Houston M.D. Anderson Cancer Center · Tests: Fludarabine phosphate, NY-ESO-1 TCR/IL-15 NK, Cyclophosphamide HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma NCT04995003Phase 11 site📍 Houston Baylor College of Medicine · Tests: T cells or CAR T cells, Pembrolizumab Injectable Product, Nivolumab Injectable Product Personalized Vaccination in Fusion+ Sarcoma Patients (PerVision) NCT06094101Phase 1, Phase 24 sites📍 Essen📍 Frankfurt am Main📍 Freiburg im Breisgau University Hospital Tuebingen · Tests: Peptide vaccine IPX Precision Medicine Approaches for Neoadjuvant Therapy in High-risk Sarcoma Patients NCT07432932n/a1 site📍 London Royal Marsden NHS Foundation Trust · Tests: Observational Translational Study Synovial Sarcoma Registry / Biospecimen Repository NCT05910307n/a1 site📍 Philadelphia Children's Hospital of Philadelphia Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma NCT05711615Phase 116 sites📍 Los Angeles📍 Los Angeles📍 Aurora National Cancer Institute (NCI) · Tests: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer NCT05492682Phase 17 sites📍 Frankfurt📍 Heidelberg📍 Tübingen Valo Therapeutics Oy · Tests: PeptiCRAd-1, Cyclophosphamide, Pembrolizumab Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors NCT06625190Phase 1, Phase 21 site📍 Gainesville University of Florida · Tests: Miltenyi CliniMACS Prodigy ® system, Zoledronic acid
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy